TrialJournal for immunotherapy of cancer2022

Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma.

Jun Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.